Great to see our new preprint out and first MS from PhD student Dan Mega. Highlights #antiviral use and MOA of a novel phlorotannin rich purified extract from seaweed against #influenza . Great #livuniives#livuninews https://t.co/Ojf8xzMd7G
Great to be in Japan ๐ฏ๐ต presenting our latest #Covid_19 data at the @jsv1953 Japanese Society for Virology meeting. @LivUni_IVES@livuninews Such welcoming hosts
Exciting new study from the lab published today! Excellent collaboration between @Bicycle_tx and academic labs to characterise new antiviral modality against #SARSCoV2 : Bicycle #antiviral#COVID19#Spike
https://t.co/ZORPbxg3DP
An off-patent liver disease drug could prevent #COVID19 infection, a new @Nature study has found.
@livuniHLS scientists played a key role in the collaborative study, which involved a unique mix of โmini-organsโ, donor organs, animal studies & patients.
https://t.co/KaFT8aK74S
This important work was a brilliant collaborative effort led by University of Cambridge.
The work undertaken by CELT scientists was a joint effort between @molvirol and @CELT_pharm.
Congratulations to everyone involved. @_AndrewOwen_@molvirol@LivUniISMIB#covid19
Great to be part of this study describing the potential of an approved, inexpensive, off-patent drug for liver disease in combatting Covid infections @LivUni_IVES@livuninews@CELTLiverpool@uk_icn#SARSCoV2 https://t.co/eqqFtq8ufW
Just published @Nature
An approved, inexpensive, off-patent drug for liver disease, UDCA, an FXR blocker, has supportive data in organoids, experimental models, and people for blocking Covid infections and/or reducing its severity https://t.co/grpNFfoP7l